In Silico analysis of compounds characterized from Pseudarthria viscida root with TNF-a

Rajan, Thinakaran
June 2012
Journal of Applied Pharmaceutical Science;Jun2012, Vol. 2 Issue 6, p125
Academic Journal
Tumour necrosis factor is a polypeptide cytokine involved in inflammation and the acute phase response. TNF-alpha is present in larger quantities in persons with rheumatoid arthritis. Direct inhibition of TNF-a by the commercial biological agents has produced significant advances in rheumatoid arthritis treatment and validated the extra-cellular inhibition of this proinflammatory cytokine as an effective therapy. However, viable leads molecule that inhibits TNF-a have not been reported . Bioinformatics is seen as an emerging field with the potential to significantly improve how drugs are found brought to the clinical trials and eventually released to the marketplace. Computer-Aided Drug Design (CADD) is a specialized discipline that uses computational methods to stimulate drug-protein interaction. Discovery studio 2.1 provides a set of protocols for predicting and analyzing the interaction between protein and ligands. Molecular Docking experiments were carried out for the compounds identified from Pseudarthria viscida root extract with TNF-alpha using Accelry's DISCOVERY STUDIO 2.1. Docking is a method which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex. Out of 13 compounds characterized from Pseudarthria viscida, only one of them docked with Tumour necrosis factor a.


Related Articles

  • Effect of bone marrow-derived CD11bF4/80 immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis. Fu, Jingjing; Zhang, Lingling; Song, Shanshan; Sheng, Kangliang; Li, Ying; Li, Peipei; Song, Shasha; Wang, Qingtong; Chu, Jianhong; Wei, Wei // Inflammation Research;May2014, Vol. 63 Issue 5, p357 

    Objective: To explore the effect of bone marrow-derived CD11bF4/80 immature dendritic cells (BM CD11bF4/80iDC) on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis (CIA). Methods: BM CD11bF4/80iDC were induced with rmGM-CSF and...

  • Guidelines for the proper use of etanercept in Japan. Miyasaka, Nobuyuki; Takeuchi, Tsutomu; Eguchi, Katsumi // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2006, Vol. 16 Issue 2, p63 

    Application of biological agents targeting inflammatory cytokines such as tumor necrosis factor-α (TNF-α) dramatically caused a paradigm shift in the treatment of rheumatoid arthritis (RA). Infliximab, a chimeric anti-TNF-α monoclonal antibody, has initially been introduced to Japan in...

  • Tumour necrosis factor-a, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis. Fr�de, T�nia Silvia; Tenconi, Patr�cia; Debiasi, Marilei Reynaud; Medeiros, Yara Santos // Mediators of Inflammation;Dec2002, Vol. 11 Issue 6, p345 

    Background and aims: Although the participation of cytokines in the pathogenesis of rheumatoid arthritis (RA) seems to be unequivocal, their relationship with current serum markers of this disease is not clear. The present study analyses whether there is any correlation between the levels of...

  • Tumour Necrosis Factor-α Blockers in Rheumatoid Arthritis: Review of the Clinical Experience. Richard-Miceli, C.; Dougados, M. // BioDrugs;2001, Vol. 15 Issue 4, p251 

    Tumour necrosis factor (TNF)-α has been found to play a central role in the pathogenesis of rheumatoid arthritis, leading to development of novel drug therapies that neutralise the deleterious effects of this cytokine. This new concept of immunobiological treatment of rheumatoid arthritis has...

  • Differential Pharmacological Behaviour of p38 Inhibitors in Regulating the LPS-Induced TNF-α Production in Human and Rat Whole Blood In Vitro. Pont-Giralt, Mercè; Godessart, Núria; Balagué, Cristina // Inflammation;Apr2011, Vol. 34 Issue 2, p119 

    p38 inhibitors are potent TNF-α suppressors in LPS-stimulated human whole blood and promote efficacy in the rat adjuvant arthritis model. However, the anti-TNF-α activity of p38 inhibitors in rat whole blood has not been explored, preventing the establishment of a potential relation...

  • Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. Yamaoka, Kunihiro; Tanaka, Yoshiya // Current Rheumatology Reviews;2011, Vol. 7 Issue 4, p306 

    Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional...

  • TNF Inhibition for Ophthalmic Indications: Current Status and Outlook. Rifkin, Lana; Birnbaum, Andrea; Goldstein, Debra // BioDrugs;2013, Vol. 27 Issue 4, p347 

    Background: Tumor necrosis factors (TNF) are a group of cytokines that play a role in systemic inflammation, stimulating the acute phase reaction. They are involved in systemic rheumatologic conditions such as rheumatoid arthritis and juvenile idiopathic arthritis, as well as ocular inflammatory...

  • Targeting TNF receptors in rheumatoid arthritis. Blüml, Stephan; Scheinecker, Clemens; Smolen, Josef S.; Redlich, Kurt // International Immunology;May2012, Vol. 24 Issue 5, p275 

    Tumour necrosis factor (TNF) is a pro-inflammatory cytokine that signals through two distinct receptors, TNFR1 and TNFR2. TNF is essentially involved in the pathogenesis of various inflammatory and autoimmune diseases. Blocking TNF, in turn, has been proven to be highly effective in treating a...

  • Induction of CCL13 expression in synovial fibroblasts underlines a significant role of oncostatin M in rheumatoid arthritis. Hintzen, C.; Quaiser, S.; Pap, T.; Heinrich, P. C.; Hermanns, H. M. // Cell Communication & Signaling;2009 Supplement 1, Vol. 7, Special section p1 

    Rheumatoid arthritis (RA) is a severe, chronic disease characterized by a profound inflammatory response that leads to both joint destruction as well as extraarticular symptoms with a significant impact on both morbidity and mortality. The cause and pathologic process underlying RA have not yet...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics